Trinity Biotech (TRIB) Long-Term Deferred Tax (2009 - 2025)

Trinity Biotech has disclosed Long-Term Deferred Tax across 17 years of filings, most recently posting $3.9 million for Q4 2025.

• Long-Term Deferred Tax for Q4 2025 came in at $3.9 million, down 96.2% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.9 million (down 96.2% YoY), and the FY2025 annual result was $3.9 million, down 96.2% from the prior year.
• Long-Term Deferred Tax came in at $3.9 million for Q4 2025 at Trinity Biotech, up from $3.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $103.3 million in Q4 2024 to a low of $694000.0 in Q3 2024.
• The 5-year median for Long-Term Deferred Tax is $3.8 million (2021), against an average of $8.8 million.
• Across the five-year window, Long-Term Deferred Tax surged 5129.87% in 2024 and plunged 96.2% in 2025, its largest moves.
• Trinity Biotech's Long-Term Deferred Tax stood at $4.1 million in 2021, then increased by 2.85% to $4.2 million in 2022, then plunged by 53.18% to $2.0 million in 2023, then soared by 5129.87% to $103.3 million in 2024, then slumped by 96.2% to $3.9 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $3.9 million (Q4 2025), $3.5 million (Q2 2025), and $103.3 million (Q4 2024), per Business Quant data.